Spyre Therapeutics (SYRE) EPS (Basic) (2015 - 2026)
Spyre Therapeutics (SYRE) posted EPS (Basic) of -$26.76 for Q1 2026, down 12.26% on a QoQ basis from -$23.84 in Q4 2025, and down 13.44% year-over-year from -$30.91 in Q1 2025.
Spyre Therapeutics (SYRE) EPS (Basic) (2015 - 2026) Analysis & Trends
Spyre Therapeutics' EPS (Basic) history runs 12 years deep, the most recent figure standing at -$26.76 for Q1 2026.
- Quarterly EPS (Basic) fell 13.44% year-over-year to -$26.76 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$69.59 (up 36.79% YoY) and the FY2025 annual result came in at -$59.17, up 28.27% from the prior year.
- EPS (Basic) was -$26.76 for Q1 2026 at Spyre Therapeutics, down from -$23.84 in the prior quarter.
- Across five years, EPS (Basic) topped out at -$0.86 in Q2 2024 and bottomed at -$85.83 in Q2 2025.
- A 5-year average of -$20.28 and a median of -$9.26 in 2022 frame the typical range for EPS (Basic).
- Annual changes were most pronounced in 2024 — EPS (Basic) soared 98.49% — and 2025, when it slumped 9914.63%.
- Spyre Therapeutics' EPS (Basic) stood at -$5.58 in 2022, then plunged by 64.07% to -$9.16 in 2023, then plunged by 143.69% to -$22.32 in 2024, then retreated by 6.78% to -$23.84 in 2025, then retreated by 12.26% to -$26.76 in 2026.
- Business Quant data shows SYRE's EPS (Basic) at -$26.76 in Q1 2026, -$23.84 in Q4 2025, and -$52.28 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Basic) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 0.00 |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 0.16 |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 0.00 |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 4.06 |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 6.99 |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | 0.00 |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 7.59 |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -2.29 |
| 10 | Spyre Therapeutics | 257.83 Mn | 257.83 Mn | - | -26.76 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -26.76 |
| Dec 31, 2025 | -23.84 |
| Sep 30, 2025 | -52.28 |
| Jun 30, 2025 | -85.83 |
| Mar 31, 2025 | -23.59 |
| Dec 31, 2024 | -22.32 |
| Sep 30, 2024 | -1.36 |
| Jun 30, 2024 | -0.86 |
| Mar 31, 2024 | -1.20 |
| Dec 31, 2023 | -9.16 |
| Sep 30, 2023 | -9.34 |
| Jun 30, 2023 | -56.79 |
| Mar 31, 2023 | -4.89 |
| Dec 31, 2022 | -5.58 |
| Sep 30, 2022 | -4.84 |
| Jun 30, 2022 | -6.79 |
| Mar 31, 2022 | -9.26 |
| Dec 31, 2021 | -7.77 |
| Sep 30, 2021 | -7.72 |
| Jun 30, 2021 | -2.60 |